Medical Cannabis Tied to Higher Risk for New Heart Rhythm Disorders
Findings seen for people with chronic pain; no association seen for acute coronary syndrome or heart failure
Findings seen for people with chronic pain; no association seen for acute coronary syndrome or heart failure
The designation was based on data from the phase 2 REDWOOD-HCM trial.
Furoscix is a pH-neutral formulation of furosemide designed for SC administration via a wearable, preprogrammed on-body drug delivery system.
Major cardiovascular adverse events were more common in the previous event subgroup, with 5.5% occurring in the aclidinium group and 6.2% in the placebo group.
A total of 339,003 unrelated individuals of white British descent with available genotype and matching genetic data from the UK Biobank cohort study were included in the study.
The researchers found that 5,731 individuals had a first AMI and 3,471 had a first stroke over 7.1 years. Social isolation was associated with higher risk of AMI and stroke.
The researchers found that ABI is an accurate test for detecting PAD in symptomatic patients, but few data were available on the accuracy of ABI for identifying asymptomatic individuals who could benefit from treatment.
At study start, 21% of the more than 7,000 EMPA-REG OUTCOME trial participants had existing peripheral artery disease.
Noninvasive testing with CCTA or stress testing also leads to more radiation exposure, greater cost
The FDA’s final approval is pending the period of patent and/or exclusivity protection, and may not be made effective until the period has expired.